Loading news...
Blackstone Life Sciences will provide $400 million to support development of duvakitug, a human monoclonal antibody targeting TL1A Duvakitug is currently in phase 3 clinical studies for ulcerative colitis (UC) and Crohn's disease (CD) Agreement supports Teva's Pivot to Growth strategy to accelerate its innovative pipeline and drive long-term growth PARSIPPANY, N.
Eli Lilly and Company's shares rose during the quarter as Zepbound's obesity launch continued to gain strong traction. Cidara Therapeutics' shares rose further following Merck's acquisition of the company in a $9.2 billion all-cash deal announced in November 2025, representing a premium of more than 100% over the prior closing price. Doximity's stock detracted from performance as the company issued disappointing guidance for the next two quarters.
Teva Pharmaceutical Industries has more than doubled in price over the past year. The Israeli drugmaker, formerly known for producing generics, has made a major move into the specialty drugs space.
Teva Pharmaceutical Industries is a large manufacturer of generic drugs. The company is working to expand into more complex generics and to develop its own drugs.
Investor attention turned more intensely to the scale, timing, and funding of AI-related capital commitments, prompting renewed debate about whether expectations were running ahead of eventual monetization. The Russell 1000 Value Index returned 3.81% during the quarter, outperforming the Russell 1000 Growth Index's return of 1.12% by nearly 270 basis points. Under its 'pivot to growth' strategy, Teva has expanded its biosimilars portfolio and strengthened its generics business, returning that segment to positive growth.
Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and ALX Oncology Holdings Inc. (ALXO) have performed compared to their sector so far this year.
PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in the upcoming investor conferences in March as follows:
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. TEV-'749 is designed to improve real-world treatment adherence and help patients maintain long-term stability, with the goal of addressing a critical treatment gap for people living with schizophrenia.
Teva Pharmaceutical Industries (TEVA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Corcept had argued that Teva's label for its generic version of Korlym, a drug used to treat Cushing's syndrome, would induce doctors to follow patented dosing methods involving mifepristone and strong CYP3A inhibitors such as ketoconazole.
Guru Stock PicksLouis Moore Bacon has made the following transactions:Reduce in XLF by 69.62%Sold out in CEGAdd in CLS by 386.7%New position in CLJoel Greenblat
Insights into Glenview Capital Management's Fourth Quarter 2025 Moves Larry Robbins (Trades, Portfolio) recently submitted the 13F filing for the fourth quarte
Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Results Transcript
Teva and Sanofi SA (NASDAQ: SNY) released positive results on Tuesday from the RELIEVE UCCD long-term extension study of duvakitug, an investigational human monoclonal antibody targeting TL1A.
Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data.
Thrivent Financial for Lutherans purchased a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 199,467 shares of the company's stock, valued at approximately $4,029,000. A number of other
Exploring the Strategic Moves of a Renowned Value Investor Francisco Garcia Parames (Trades, Portfolio), a prominent figure in the world of value investing, re
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA - Get Free Report)'s stock price reached a new 52-week high on Thursday after the company announced better than expected quarterly earnings. The company traded as high as $33.43 and last traded at $32.5270, with a volume of 2202319 shares changing hands. The stock had previously closed at $33.21. The
Teva beats Q4 estimates driven by a Sanofi milestone and strong Austedo growth. The drugmaker also unveils its 2026 outlook.
Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call Transcript